[The mechanism of the efficiency of leukocytapheresis on rheumatoid arthritis].
Several clinical trials revealed that leukocytapheresis (LCAP) was safe and effective therapy for patients with rheumatoid arthritis (RA). In this article, the mechanism of the efficiency of LCAP on RA is reviewed. The counts of activated CD4(+) T cells and CD4(+)CD29(+) T cells were significantly reduced in the synovial fluid after LCAP. Serum tumor necrosis factor alpha, interleukin (IL)-15 and RANTES were significantly reduced, while serum IL-10 significantly increased and this level increased significantly only in the responder group after treatment. P-glycoprotein (Pgp), which causes drug resistance by exclusion of intracellular drugs, expression on Th1 cells following LCAP therapy was significantly decreased after 4 sessions of treatment and 6 months after the last procedure in the responder group. Moreover, remarkable improvements of regulatory T cell (Treg) function were observed in good responders. Our findings suggest that LCAP may cause a reduction of activated T cells from affected joints, down-regulation of Pgp on helper T cells and restoration of Treg function, and that may modify the abnormal cytokine balance. These findings may explain some of the mechanisms by which the articular symptoms are improved by LCAP.
Institute of Rheumatology, Zenjinkai Shimin-no-mori Hospital, Japan.
Toshihiko
T
Hidaka
D001172:Arthritis, Rheumatoid / Q000276:immunology* / Q000628:therapy; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000276:immunology; D006801:Humans; D007937:Leukapheresis; D008213:Lymphocyte Activation; D013601:T-Lymphocytes / Q000276:immunology
D016207:Cytokines